VivoSeq
Cardiovascular

Atherosclerosis

133

Pipeline Programs↗

30

Active Trials↗

45

Companies Involved↗

Atherosclerosis is a highly competitive landscape with 133 programs across 45 companies. The most active players are Azurity Pharmaceuticals, BioMarin Pharmaceutical, Bristol-Myers Squibb. 38 therapies are approved with 39 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

75/100

Pipeline Velocity

37/100

Mech. Concentration

13/100

Completion Rate

79/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Azurity Pharmaceuticals

1 program

Phase 1BioMarin Pharmaceutical logo

BioMarin Pharmaceutical

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

3 programs

Phase 2K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

2 programs

Phase 2S

Sankyo Pharma Gmbh

1 program

Phase 2C

Cerenis Therapeutics, SA

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

93%

Small molecule

150 of 162 classified programs — the dominant modality here.

7%ALL OTHERSMonoclonal antibody42%Protein / enzyme21%Peptide21%RNA therapy21%Vaccine1<1%Radiopharmaceutical1<1%

Small molecule leads; the ring shows all 162 classified programs, each share of the total. Modality classified for 99% of 166 pipeline programs.

Analysis

Trial Status

156

clinical trials

Completed81 · 52%
Unknown status24 · 15%
Recruiting18 · 12%
Terminated13 · 8%
Not yet recruiting9 · 6%
Withdrawn7 · 4%
Other4 · 3%

Clinical Trials

Trial Activity

156 trials

Clinical Research Protocol of Ferumoxytol for Magnetic Resonance Enhancement Imaging in Patients With Atherosclerosis.
Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·N/A·NCT06551805·100 enrolled
Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia
Recruiting·SSeoul National University Bundang Hospital·Phase 4·NCT05365438·105 enrolled
Efficacy and Safety of the Regulatory Polypeptides in Patients With Peripheral Atherosclerosis.
Recruiting·RRyazan State Medical University·N/A·NCT05933720·120 enrolled
Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT05476991·2,800 enrolled
Remote Ischemic Conditioning for Acute Moderate Ischemic Stroke Due to Large Artery Atherosclerosis
Recruiting·FFirst Affiliated Hospital Xi'an Jiaotong University·N/A·NCT06775782·1,150 enrolled
The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis
Recruiting·—·Phase 4·NCT06757764·2,340 enrolled
Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis
Recruiting·NNational University of Singapore·Phase 2/3·NCT07282041·130 enrolled
Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis
Recruiting·TTongji Hospital·N/A·NCT04847752·1,000 enrolled
PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis
Recruiting·PPeking Union Medical College Hospital·Phase 4·NCT06902740·300 enrolled
Early Statin-Ezetimibe Combination vs. Statin Monotherapy in Stroke With Atherosclerosis
Recruiting·—·Phase 2·NCT07307989·300 enrolled
PET Detection of CCR2 in Human Atherosclerosis
Recruiting·WWashington University School of Medicine·Phase 1·NCT04537403·100 enrolled
Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia
Recruiting·SSeoul National University Bundang Hospital·Phase 4·NCT05365425·56 enrolled
Fractional Flow Reserve to Determine Atherosclerosis Renovascular Hypertension Stenting
Recruiting·PPeking University First Hospital·N/A·NCT05732077·100 enrolled
Metabolic and Metagenomic Effects of Intestinal Microbiome Repopulation in Unexplained Atherosclerosis
Recruiting·WWestern University, Canada·Phase 1·NCT04410003·100 enrolled
Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis
Recruiting·SSeoul National University Bundang Hospital·Phase 4·NCT06399835·120 enrolled
Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)